Search

For those living with advanced cancer, quality of life means pursuing what matters most to each person — whether that’s making art, running marathons, caring for others, or spending more time with family.

… Friday, June 6, 2025 Cancer that spreads from an initial tumor to other parts of the body — known as metastasis — is a daunting diagnosis that brings with it a great deal of fear and uncertainty. While metastatic cancer remains challenging, significant advances in diagnosis and treatment are making it

Visible Ink at Memorial Sloan Kettering Cancer Center (MSK) is the leading — and largest — writing program of its kind. Writing promotes creativity, reduces stress, and empowers people with cancer to give voice to their stories.

… Friday, April 6, 2018 Visible Ink at Memorial Sloan Kettering Cancer Center (MSK) is the leading — and largest — writing program of its kind. Writing promotes creativity, reduces stress, and empowers people with cancer to give voice to their stories. On Monday, April 16 at 6:30 p.m. , the Kaye Playhouse

Dr. Perales was formally sworn in during the 2023 Tandem Transplantation and Cellular Therapy Meetings of ASTCT and the Center for International Blood and Marrow Transplant Research (CIBMTR) on February 18.

… Monday, February 20, 2023 Miguel-Angel Perales, MD , of Memorial Sloan Kettering Cancer Center (MSK), has been named President of The American Society for Transplantation and Cellular Therapy (ASTCT) for 2023-2024. Dr. Perales was formally sworn in during the 2023 Tandem Transplantation and Cellular

Memorial Sloan Kettering Cancer Center (MSK) today celebrated the opening of a $1.5 billion state-of-the-art cancer treatment facility with government officials, members of the Boards of Overseers and Managers, and staff. Opening for patient care next month, the 750,000-square-foot building is the institution’s — and the city’s — largest freestanding cancer care facility. The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center is a healing community dedicated to patient-centered care, made possible by a landmark donation and a pioneering vision that signifies a new era of cancer care.

… Tuesday, December 10, 2019 Memorial Sloan Kettering Cancer Center (MSK) today celebrated the opening of a $1.5 billion state-of-the-art cancer treatment facility with government officials, members of the Boards of Overseers and Managers, and staff. Opening for patient care next month, the 750,000-square-foot

Learn how MSK works to keep people with cancer heart healthy.

… Thursday, February 13, 2020 Summary People with cancer are at a significantly higher risk of heart disease during and after treatment. The issue has taken on more importance because people are living longer after a cancer diagnosis. Cancer is challenging enough on its own. Now, a recent study published

New MSK research supported the approval of a new treatment for ER-positive, HER2-negative advanced breast cancer; suggests a new strategy for overcoming resistance to Akt inhibitors in patients with PTEN-mutated prostate cancers; provides new understanding of B cell lymphomas that could lead to new treatments; examines using ChatGPT to help capture patient-reported outcomes; and developed the first customizable, scalable model for palliative care training for emergency departments.

… Thursday, February 13, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) supported the approval of a new treatment for ER-positive, HER2-negative advanced breast cancer; suggests a new strategy for overcoming resistance to Akt inhibitors in patients with PTEN -mutated prostate cancers

Research by a team at Memorial Sloan Kettering Cancer Center has found important new insights into colorectal cancer in Nigeria that have significant implications for treating the disease in West Africa. This research also expands awareness of how different population groups may require different approaches in the diagnosis and treatment of cancer.

… Wednesday, November 24, 2021 Colorectal cancer is common — and deadly — around the world.   But too often, major population groups are not represented in colorectal cancer research, which focuses mainly on patients in America and Western Europe.   A team of researchers from Memorial Sloan Kettering Cancer

The Patient and Family Advisory Council for Quality (PFACQ) marks five years of ensuring the patient and family perspective is included in everything MSK does.

… Wednesday, January 1, 2020 In 2014, Kate Niehaus, a former patient active in volunteer work for Memorial Sloan Kettering, was approached by Kent Sepkowitz, an infectious disease specialist and Deputy Physician-in-Chief for Quality and Safety, with a proposal to make MSK’s outstanding cancer care even

Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries molecular changes called NPM1 mutations and KMT2A translocations.

… Wednesday, October 29, 2025 On October 24, 2025, the U.S. Food and Drug Administration (FDA)  approved revumenib (Revuforj ® ) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries a molecular change called an NPM1 mutation. In November 2024,

Mutations that drive cancer growth also make a cell more noticeable to the immune system.

… Wednesday, May 11, 2022 Many cancers contain similar genetic “hotspots” — areas of DNA that are likely to be mutated. For example, more than 50% of cancers contain a mutation in a gene called TP53 , often within a narrow DNA range. Researchers know that hotspots can contribute to cancer development and